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Dr R. Duane Davis (Durham, NC). Dr Rastan and colleagues
have reported on a large cohort of patients with PCS supported
by ECMO. Not surprisingly, for this difficult group of patients,
this experience featured substantial mortality and morbidity, partic-
ularly bleeding and thromboembolic complications. The hospital
survival of approximately 25% is similar to numerous previous re-
ports as well as to registry data, which are approximately in the 30%
to 35% range. So their results are well within the range of what we
would expect. My questions are going to be related first to technical
issues, second to patient selection issues, and third to overall stra-
tegic issues.
First, Dr Rastan, you have suggested that ongoing shock, as
manifested by lactate levels that are increasing or high at the begin-
ning, is associated with worse outcomes in terms of mortality. Is
this an opportunity? That is, do you have data to suggest that if
you are able to increase the performance while on ECMO by in-
creasing ECMO flow rates or improving the blood pressure that
you can actually improve outcomes? From that standpoint, is there
a strategy when you have ongoing higher lactate levels or shock of310 The Journal of Thoracic and Cardiovascular Surgaltering cannula positions or other things to try to improve ECMO
performance?
Dr Rastan. This is an important point. What we sometimes
found in our experience is that we had some problems with the ve-
nous backflow to the ECMO system if we used femoral cannulation
sites. As a consequence, this was one of the main reasons for
ECMO revision. In these patients, we found an ongoing high lactate
level during the first 24 hours because we had a flow of only 80% to
90% of the cardiac output. This was in a few patients an indication
for reopening the chest to put in a right atrial cannulation. So in ad-
dition to bleeding, compromised ECMOflowwas indeed one of the
most important reasons for ongoing high lactate levels, and we
could show that this was associated with extremely high mortality.
Dr Davis. Let me follow up on that. Have you changed your
strategy during the years—earlier implantation, more open-chest
procedures, more central cannulation—or is it still a kind of mish-
mash of approaches to these patients?
Dr Rastan. Yes, we changed our policy twice. With the intro-
duction of long venous femoral cannulas, our policy changed to
close the chest and to use peripheral cannulation—axillary or fem-
oral arterial cannulation—to reduce bleeding complications. In our
experience, however, some of these patients had suboptimal
ECMO flow, so we changed the strategy again and used thoracic
cannulation more liberally to allow an optimal ECMO flow.
The latter strategy is also supported by the experience that even
with peripheral cannulation and a closed chest, most of the pa-
tients required rethoracotomy because of hematoma, which com-
promised the cardiac function, whereas there was bleeding and
a low infection rate in open-chest patients. So we think that clos-
ing the chest is not the primary goal for every patient undergoing
ECMO.
Dr Davis. My second question really regards patient selection.
When is the use of ECMO really going to be futile? You have
shown a statistical analysis, which basically assumes a linear rela-
tionship with a number of variables, but we all know that for age,
for instance, the relationship may be linear for a long time, but as
you approach the 70s and 80s it actually becomes more of an expo-
nential relationship. That is, would you put an 80-year-old patient
on ECMO after dissection repair in your institution? Whom do you
exclude?
Dr Rastan. This is a difficult point. Our policy was to use
ECMO liberally in PCS situations. We put not all but almost all pa-
tients in PCS on ECMO. This included older patients, allowing
them cardiac recovery for at least 2 to 3 days. If this failed and
the cardiac failure persisted, we withdrew ECMO therapy in
consensus with the families.
I think that especially in unexpected PCS, that is, for patients
with primary good cardiac function or after uneventful early post-
operative course, there is a good chance for cardiopulmonary re-
covery. This is why we do not reject implantation of ECMO
even for an older patient. What we have to rethink, however, on
the basis of these data is whether after complex valve or aortic pro-
cedures with a high bleeding rate we should decide to turn down
ECMO or withdraw it earlier.
Dr Davis. My final question regards the appropriate strategy in
2009 or 2010 for the support of a patient after PCS? In this series,
you didn’t have a substantial improvement during the 12-year pe-
riod. If you look at the literature, there also doesn’t appear to be
much of an improvement during that period. Your 6-month survivalery c February 2010
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Dis only 16%or 17%,whichmay be acceptable versus the alternative,
but is that really where we should be headed? Can’t we do better?
Now, this question is kind of multiphase. It has to do with some
institutional bias in that we try to direct our therapy to what is fail-
ing. That is, if it is a left ventricular failure, we’ll put an L-VAD in;
if it is a left ventricular failure, if it is a right ventricular failure, we’ll
put a right VAD in; if it is just pulmonary, parenchymal, or gas ex-
change, then we use venovenous ECMO. We use venoarterial
ECMO more along the lines of 2 or 3 failures, right ventricle, left
ventricle, lung. Do you have an approximation of how many of
the patients had right ventricular failure, left ventricular failure, pa-
renchymal failure, or a combination? And are you moving away
from using venoarterial ECMO to some of the other treatment
modalities? You may actually have more tools in your chest than
we have in the United States.
Dr Rastan. First, our data revealed an improved survival gain
during the last 3 years in our institution, which I didn’t show
here. We all know that the survival and the success of ECMO de-
pends heavily on patient selection. In other words, if you include
unfavorable patients in your cohort and implant ECMO, you will
have a bad outcome. So the results depend strongly on the indica-
tion and the selection before the ECMO implantation. As I demon-
strated, we used ECMO liberally and included some very poor
candidates. Surprisingly, a significant number even of these
patients survived.
The reasons we preferentially used ECMO rather than other life-
saving systems, especially for the postoperative indications, were
that we can implant it quickly, that ECMO fits all patients, and
that ECMO covers both right and left ventricular as well as pulmo-
nary failure, which sometimes is difficult to distinguish in an emer-
gency situation. I agree with you that if you can fix left ventricular
failure, maybe a centrifugal pump just for support of the left ventri-
cle might be the better option to reduce systemic inflammatory re-
sponse syndrome or the high bleeding rate. This is difficult to fix inThe Journal of Thoracic and Caan individual situation or under resuscitation, however, so our
policy is to use ECMO more often than isolated centrifugal pumps.
Not surprisingly, we found left ventricular failure in most of our
patients. For patients with right ventricular failure, we had the ex-
perience that cardiac recovery was more prolonged or failure more
frequent. Thus patients with right heart failure had worse outcome
than patients with left ventricular failure.
In a total of 15 younger patients, we implanted an L-VAD as
a bridge-to-bridge therapy. To be honest, though, these data were
unsatisfactory. We lost 12 of these 15 patients in the postoperative
course. Maybe the concept is to fix the problem as fast as possible
under ECMO and then to switch as early as possible to a more du-
rable system if the patient is a transplantion candidate. Most of our
patients were not transplantion candidates, or were poor candidates,
as I could demonstrate to you. A lot of our patients had emergency
or urgent indications for surgery.
Dr Davis. I guess my comment with regard to ECMO and trying
to get left ventricular recovery is it is really not an unloading strat-
egy. It is, rather, a loading strategy, and then you throw in all the
thromboembolic complications that run with having essentially
a membrane oxygenator and circuit, it seems to be a bit problem-
atic. But my congratulations on an excellent presentation.
Dr Thorsten Hanke (Lu¨beck, Germany). I have a single ques-
tion. There was a difference between patients in whom you im-
planted the ECMO early in the operating room and those in
whom you did it after 2 or 3 days. Has there been a difference in
the outcome between those patient groups?
Dr Rastan. No. Just a short answer. This was interesting, be-
cause there might be a difference in patient characteristics between
patients who received ECMO because they were not able to be
weaned from cardiopulmonary bypass and other patients who
had primarily good or acceptable condition with an IABP and
low catecholamines and then had PCS. But this event per se was
not an indicator for hospital mortality in univariate analysis.rdiovascular Surgery c Volume 139, Number 2 311
